183 related articles for article (PubMed ID: 3199841)
21. Remission induction with cytarabine and daunorubicin with or without 6-thioguanine in adult patients with acute myelocytic leukemia.
Nowrousian MR; Pfeiffer R; Schaefer UW; Osieka R; Niederle N; Anders C; Schmidt CG
Haematol Blood Transfus; 1987; 30():352-5. PubMed ID: 3305206
[No Abstract] [Full Text] [Related]
22. Progress in acute myelogenous leukemia.
Gale RP
Cancer Treat Rep; 1981; 65 Suppl 4():87-92. PubMed ID: 7049383
[TBL] [Abstract][Full Text] [Related]
23. Pattern of bone marrow regeneration following chemotherapy for acute myeloid leukemia.
Islam A
J Med; 1987; 18(2):108-22. PubMed ID: 3480927
[TBL] [Abstract][Full Text] [Related]
24. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
[TBL] [Abstract][Full Text] [Related]
25. Cellular pharmacokinetics of daunomycin in human leukemic blasts in vitro and in vivo.
Scheulen ME; Kramer B; Skorzec M; Reich WK
Haematol Blood Transfus; 1990; 33():122-8. PubMed ID: 2323624
[No Abstract] [Full Text] [Related]
26. Post consolidation therapy for adult patients with acute myeloid leukaemia.
Ranson MR; Scarffe JH; Morgenstern GR; Chang J; Anderson H; Deakin DP; Oppenheim B; Heron D; Ryder D
Br J Haematol; 1991 Oct; 79(2):162-9. PubMed ID: 1958473
[TBL] [Abstract][Full Text] [Related]
27. Differentiation induction in myelodysplasia and acute myeloid leukaemia: use of synergistic drug combinations.
Francis GE; Mufti GJ; Knowles SM; Berney JJ; Guimaraes JE; Secker-Walker LM; Hamblin TJ
Leuk Res; 1987; 11(11):971-7. PubMed ID: 3480401
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
[TBL] [Abstract][Full Text] [Related]
29. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia.
Venditti A; Stasi R; Del Poeta G; Buccisano F; Aronica G; Bruno A; Pisani F; Caravita T; Masi M; Tribalto M
Leukemia; 1995 Jul; 9(7):1121-5. PubMed ID: 7630182
[TBL] [Abstract][Full Text] [Related]
30. Fractionated anthracycline therapy in acute myeloblastic leukaemia in adults.
Donohue SM; Boughton BJ
Cancer Chemother Pharmacol; 1989; 23(6):401-2. PubMed ID: 2713963
[TBL] [Abstract][Full Text] [Related]
31. Aclacinomycin, cytosine arabinoside and thioguanine in relapsed or resistant acute myeloid leukemia.
Neri A; Comis M; Brugiatelli M; Martino B; Ronco F
Haematologica; 1989; 74(1):113-4. PubMed ID: 2498174
[No Abstract] [Full Text] [Related]
32. The nature of remission in acute myeloblastic leukaemia.
Powles RL; Selby PJ; Palu G; Morgenstern G; McElwain TJ; Clink HM; Alexander P
Lancet; 1979 Sep; 2(8144):674-6. PubMed ID: 90762
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.
Lacayo NJ; Alonzo TA; Gayko U; Rosen DB; Westfall M; Purvis N; Putta S; Louie B; Hackett J; Cohen AC; Cesano A; Gerbing R; Ravindranath Y; Dahl GV; Gamis A; Meshinchi S
Br J Haematol; 2013 Jul; 162(2):250-62. PubMed ID: 23682827
[TBL] [Abstract][Full Text] [Related]
34. [Comparative analysis of 3 therapeutic regimens based on the combination of an anthracycline and cytosine arabinoside for remission induction in myeloblastic leukemia].
Sanz MA; Lorenzo JI; Sanz GF; Martín Aragonés G; Rafecas FJ; Martínez JA; Gomis F
Sangre (Barc); 1988 Dec; 33(6):497-504. PubMed ID: 3247626
[No Abstract] [Full Text] [Related]
35. The criteria for bone marrow recovery post-myelosuppressive therapy for acute myelogenous leukemia: a quantitative study.
Khalil F; Cualing H; Cogburn J; Miles L
Arch Pathol Lab Med; 2007 Aug; 131(8):1281-9. PubMed ID: 17683190
[TBL] [Abstract][Full Text] [Related]
36. Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia.
Preisler HD; Azarnia N; Raza A; Grunwald H; Vogler R; Browman G; Goldberg J; Chervenick P; Miller K; Brennan J
Br J Haematol; 1984 Mar; 56(3):399-407. PubMed ID: 6582925
[TBL] [Abstract][Full Text] [Related]
37. Contribution of clonogenic leukemic cell characteristics to therapy outcome in patients with acute myeloblastic leukemia.
Aul C; Heyll A
Haematol Blood Transfus; 1987; 30():356-60. PubMed ID: 3476367
[No Abstract] [Full Text] [Related]
38. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.
Larson RA; Day RS; Azarnia N; Bennett JM; Browman G; Goldberg J; Gottlieb A; Grunwald H; Miller K; Raza A
Br J Haematol; 1992 Oct; 82(2):337-46. PubMed ID: 1419816
[TBL] [Abstract][Full Text] [Related]
39. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
40. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.
Woods WG; Ruymann FB; Lampkin BC; Buckley JD; Bernstein ID; Srivastava AK; Smithson WA; Benjamin DR; Feig SA; Kim TH
Cancer; 1990 Sep; 66(6):1106-13. PubMed ID: 2205352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
